BiotechTube

EDIT-101

Phase 1/2UNKNOWN
1 views this week 0 watching💤 Quiet
Interest: 18/100
18
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Leber Congenital Amaurosis 10

Conditions

Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies, Eye Diseases, Hereditary, Retinal Disease, Retinal Degeneration, Vision Disorders, Eye Disorders Congenital

Trial Timeline

Sep 26, 2019 → May 23, 2025

NCT ID
NCT03872479

About EDIT-101

EDIT-101 is a phase 1/2 stage product being developed by Editas Medicine for Leber Congenital Amaurosis 10. The current trial status is unknown. This product is registered under clinical trial identifier NCT03872479. Target conditions include Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies, Eye Diseases, Hereditary.

What happened to similar drugs?

1 of 5 similar drugs in Leber Congenital Amaurosis 10 were approved

Approved (1) Terminated (1) Active (3)
✅IdebenoneSanthera PharmaceuticalsApproved
❌Idebenone + PlaceboSanthera PharmaceuticalsPhase 3
🔄GS010GenSight BiologicsPhase 3
🔄GS010GenSight BiologicsPhase 3
🔄PlaceboGenSight BiologicsPhase 3

Hype Score Breakdown

Clinical
9
Activity
4
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03872479Phase 1/2UNKNOWN

Competing Products

12 competing products in Leber Congenital Amaurosis 10

See all competitors
ProductCompanyStageHype Score
AAV RPE65MeiraGTxPhase 1/2
26
AAV OPTIRPE65MeiraGTxPre-clinical
20
Idebenone + PlaceboSanthera PharmaceuticalsPhase 2
25
IdebenoneSanthera PharmaceuticalsApproved
33
Idebenone 150 MG Oral TabletSanthera PharmaceuticalsPre-clinical
16
IdebenoneSanthera PharmaceuticalsPre-clinical
16
sepofarsenProQRPhase 2/3
24
sepofarsenProQRPhase 2/3
32
Idebenone + PlaceboSanthera PharmaceuticalsPhase 3
22
GS010GenSight BiologicsPhase 3
30
GS010GenSight BiologicsPhase 3
30
PlaceboGenSight BiologicsPhase 3
30